Jordan's Hikma Sees Double-digit Sales Growth In First Half, Continues Aggressive M&A Expansion In Middle East
This article was originally published in PharmAsia News
Executive Summary
Hikma, one of the fastest growing multinational pharmaceutical companies, reported group revenue Aug. 26 up 11.3 percent year-on-year for the first half of 2010. Diversified among branded, generic and injectables, the Jordanian drug maker attributed the growth to strong generics sales in the U.S
You may also be interested in...
Hospira Hinges Emerging Market Success On Scale And Differentiation
Hospira Inc.'s new CEO Michael Ball laid out the company's strategic moves to expand in the fast-growing emerging markets during the company's Sept. 7 Investor's Day conference. The CEO said the U.S.-centric company's future growth hinges on expanding its footprint in emerging markets and launching more products including biosimilars in top pharmaceutical markets in Europe and Japan
Hospira Hinges Emerging Market Success On Scale And Differentiation
Hospira Inc.'s new CEO Michael Ball laid out the company's strategic moves to expand in the fast-growing emerging markets during the company's Sept. 7 Investor's Day conference. The CEO said the U.S.-centric company's future growth hinges on expanding its footprint in emerging markets and launching more products including biosimilars in top pharmaceutical markets in Europe and Japan
Pharmas Assess Impact In Egypt; Local Player Hikma Less Exposed, Say Analysts
As drug makers restart their Egyptian operations, financial analysts have begun to assess the impact of recent events for the pharma industry. As the largest pharma market in the Middle East, Egypt has attracted both multinational and local drug makers, but local firms such as leading Jordanian pharma Hikma may see less disruption from political events than MNC counterparts, according to Credit Suisse analysts